# Apatinib Plus XELOX as Neoadjuvant Therapy in Locally Advanced Gastric Cancer

> **NCT03229096** · PHASE2 · UNKNOWN · sponsor: **Shanghai Zhongshan Hospital** · enrollment: 35 (estimated)

## Conditions studied

- Chemotherapy Effect
- Chemotherapeutic Toxicity
- Gastric Cancer

## Interventions

- **DRUG:** Apatinib plus XELOX

## Key facts

- **NCT ID:** NCT03229096
- **Lead sponsor:** Shanghai Zhongshan Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-02-01
- **Primary completion:** 2021-11-01
- **Final completion:** 2021-12-01
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2019-06-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03229096

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03229096, "Apatinib Plus XELOX as Neoadjuvant Therapy in Locally Advanced Gastric Cancer". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT03229096. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*